Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07601100 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT07601100 is a Phase 1 study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 88 participants.
The verdict
NCT07601100, a Phase 1 study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study is to evaluate the combination of isatuximab, iberdomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma participants who are transplant ineligible or not intended for upfront transplant. The names of the study drugs used in this research study are: isatuximab, iberdomide, bortezomib dexamethasone
Interventions
- DRUG Isatuximab
- DRUG Iberdomide
- DRUG Bortezomib
- DRUG Dexamethesone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2026-06-26 |
| Est. Completion | 2034-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07601100
The ClinicalTrials.gov registry entry for NCT07601100 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Isatuximab is the first listed.
NCT07601100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07601100 about?
NCT07601100 is a clinical study titled "Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma". This study is to evaluate the combination of isatuximab, iberdomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma participants who are transplant ineligible or not intended for upfront transplant. The names of the study drugs used in this research study are: isatuximab, iberdo...
What is the current status of trial NCT07601100?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2026-06-26. Estimated completion is 2034-07-01.
What interventions are being tested in trial NCT07601100?
The interventions under investigation include: Isatuximab (DRUG), Iberdomide (DRUG), Bortezomib (DRUG), Dexamethesone (DRUG).
Who is sponsoring clinical trial NCT07601100?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.